Putting an 'End' to HIV mRNAs: Capping and polyadenylation as potential therapeutic targets

AIDS Research and Therapy

Volumn 10, Issue 1, 2013, Pages

  Wilusz, Jeffrey ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

3 end formation; Capping; HIV; Polyadenylation; Post transcriptional control

Indexed keywords

MESSENGER RNA; MESSENGER RNA PRECURSOR; POLYNUCLEOTIDE ADENYLYLTRANSFERASE; RNA POLYMERASE II; SMALL NUCLEAR RNA; TRANSACTIVATOR PROTEIN; VIRUS RNA;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; BIOGENESIS; CARBOXY TERMINAL SEQUENCE; CELL NUCLEUS; CYTOPLASM; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MAMMAL CELL; MOLECULAR BIOLOGY; NONHUMAN; OPEN READING FRAME; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RNA BINDING; RNA CAPPING; RNA INTERFERENCE; RNA METHYLATION; RNA SPLICING; RNA STRUCTURE; RNA TRANSLATION; TRANSCRIPTION ELONGATION; UPREGULATION; VIRUS REPLICATION;

EID: 84890252755     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-10-31     Document Type: Review

References (81)

1. Darnell JE. Reflections on the history of pre-mRNA processing and highlights of current knowledge: a unified picture. RNA 2013, 19:443-460. 10.1261/rna.038596.113, 23440351.
2. Lenasi T, Barboric M. Mutual relationships between transcription and pre-mRNA processing in the synthesis of mRNA. Wiley Interdiscip Rev RNA 2013, 4:139-154. 10.1002/wrna.1148, 23184646.
3. Martinez NM, Lynch KW. Control of alternative splicing in immune responses: many regulators, many predictions, much still to learn. Immunol Rev 2013, 253:216-236. 10.1111/imr.12047, 23550649.
4. Lutz CS, Moreira A. Alternative mRNA polyadenylation in eukaryotes: an effective regulator of gene expression. Wiley Interdiscip Rev RNA 2011, 2:22-31. 10.1002/wrna.47, 21956967.
5. Cullen BR. Nuclear mRNA export: insights from virology. Trends Biochem Sci 2003, 28:419-424. 10.1016/S0968-0004(03)00142-7, 12932730.
6. Haimovich G, Medina DA, Causse SZ, Garber M, Millán-Zambrano G, Barkai O, Chávez S, Pérez-Ortín JE, Darzacq X, Choder M. Gene expression is circular: factors for mRNA degradation also foster mRNA synthesis. Cell 2013, 153:1000-1011. 10.1016/j.cell.2013.05.012, 23706738.
7. Lee JE, Lee JY, Trembly J, Wilusz J, Tian B, Wilusz CJ. The PARN deadenylase targets a discrete set of mRNAs for decay and regulates cell motility in mouse myoblasts. PLoS Genet 2012, 8:e1002901. 10.1371/journal.pgen.1002901, 3431312, 22956911.
8. de Breyne S, Soto-Rifo R, López-Lastra M, Ohlmann T. Translation initiation is driven by different mechanisms on the HIV-1 and HIV-2 genomic RNAs. Virus Res 2013, 171:366-381. 10.1016/j.virusres.2012.10.006, 23079111.
9. Refsland EW, Harris RS. The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol 2013, 371:1-27.
10. Klase Z, Houzet L, Jeang KT. MicroRNAs and HIV-1: complex interactions. J Biol Chem 2012, 287:40884-40890. 10.1074/jbc.R112.415448, 3510792, 23043098.
11. Tazi J, Bakkour N, Marchand V, Ayadi L, Aboufirassi A, Branlant C. Alternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action. FEBS J 2010, 277:867-876. 10.1111/j.1742-4658.2009.07522.x, 20082634.
12. Suh MH, Meyer PA, Gu M, Ye P, Zhang M, Kaplan CD, Lima CD, Fu J. A dual interface determines the recognition of RNA polymerase II by RNA capping enzyme. J Biol Chem 2010, 285:34027-34038. 10.1074/jbc.M110.145110, 2962502, 20720002.
13. Picard-Jean F, Bougie I, Shuto S, Bisaillon M. The immunosuppressive agent mizoribine monophosphate is an inhibitor of the human RNA capping enzyme. PLoS One 2013, 8:e54621. doi:10.1371/journal.pone.0054621, 10.1371/journal.pone.0054621, 3547949, 23349942.
14. Ghosh A, Shuman S, Lima CD. Structural insights to how mammalian capping enzyme reads the CTD code. Mol Cell 2011, 43:299-310. 10.1016/j.molcel.2011.06.001, 3142331, 21683636.
15. Jiao X, Chang JH, Kilic T, Tong L, Kiledjian M. A mammalian pre-mRNA 5′ end capping quality control mechanism and an unexpected link of capping to pre-mRNA processing. Mol Cell 2013, 50:104-115. 10.1016/j.molcel.2013.02.017, 23523372.
16. Davidson L, Kerr A, West S. Co-transcriptional degradation of aberrant pre-mRNA by Xrn2. EMBO J 2012, 31:2566-2578. 10.1038/emboj.2012.101, 3365414, 22522706.
17. Viladevall L, St Amour CV, Rosebrock A, Schneider S, Zhang C, Allen JJ, Shokat KM, Schwer B, Leatherwood KH, Fisher RP. TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast. Mol Cell 2009, 33:738-751. 10.1016/j.molcel.2009.01.029, 2693121, 19328067.
18. Yang Q, Gilmartin GM, Doublié S. The structure of human cleavage factor I(m) hints at functions beyond UGUA-specific RNA binding: a role in alternative polyadenylation and a potential link to 5′ capping and splicing. RNA Biol 2011, 8:7487-53.
19. Flaherty SM, Fortes P, Izaurralde E, Mattaj IW, Gilmartin GM. Participation of the nuclear cap binding complex in pre-mRNA 3′ processing. Proc Natl Acad Sci U S A 1997, 94:11893-11898. 10.1073/pnas.94.22.11893, 23648, 9342333.
20. Lenasi T, Peterlin BM, Barboric M. Cap-binding protein complex links pre-mRNA capping to transcription elongation and alternative splicing through positive transcription elongation factor b (P-TEFb). J Biol Chem 2011, 286:22758-22768. 10.1074/jbc.M111.235077, 3123043, 21536667.
21. Lenasi T, Barboric M. Mutual relationships between transcription and pre-mRNA processing in the synthesis of mRNA. Wiley Interdiscip Rev RNA 2013, 4:139-154. 10.1002/wrna.1148, 23184646.
22. Topisirovic I, Svitkin YV, Sonenberg N, Shatkin AJ. Cap and cap-binding proteins in the control of gene expression. Wiley Interdiscip Rev RNA 2011, 2:277-298. 10.1002/wrna.52, 21957010.
23. Ling SH, Qamra R, Song H. Structural and functional insights into eukaryotic mRNA decapping. Wiley Interdiscip Rev RNA 2011, 2:193-208. 10.1002/wrna.44, 21957006.
24. Stahla-Beek HJ, April DG, Saeedi BJ, Hannah AM, Keenan SM, Geiss BJ. Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme. J Virol 2012, 86:8730-8739. 10.1128/JVI.00384-12, 3421717, 22674988.
25. Ferron F, Decroly E, Selisko B, Canard B. The viral RNA capping machinery as a target for antiviral drugs. Antiviral Res 2012, 96:21-31. 10.1016/j.antiviral.2012.07.007, 22841701.
26. Ott M, Geyer M, Zhou Q. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 2011, 10:426-435. 10.1016/j.chom.2011.11.002, 3478145, 22100159.
27. Sanghvi VR, Steel LF. A re-examination of global suppression of RNA interference by HIV-1. PLoS One 2011, 6:e17246. doi:10.1371/journal.pone.0017246, 10.1371/journal.pone.0017246, 3046114, 21386885.
28. Jablonski JA, Amelio AL, Giacca M, Caputi M. The transcriptional transactivator Tat selectively regulates viral splicing. Nucleic Acids Res 2010, 38:1249-1260. 10.1093/nar/gkp1105, 2831323, 19966273.
29. Chiu YL, Coronel E, Ho CK, Shuman S, Rana TM. HIV-1 Tat protein interacts with mammalian capping enzyme and stimulates capping of TAR RNA. J Biol Chem 2001, 276:12959-12966. 10.1074/jbc.M007901200, 11278368.
30. Chiu YL, Ho CK, Saha N, Schwer B, Shuman S, Rana TM. Tat stimulates cotranscriptional capping of HIV mRNA. Mol Cell 2002, 10:585-597. 10.1016/S1097-2765(02)00630-5, 12408826.
31. Zhou M, Deng L, Kashanchi F, Brady JN, Shatkin AJ, Kumar A. The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA. Proc Natl Acad Sci USA 2003, 100:12666-12671. 10.1073/pnas.1835726100, 240675, 14569024.
32. Kuciak M, Gabus C, Ivanyi-Nagy R, Semrad K, Storchak R, Chaloin O, Muller S, Mély Y, Darlix JL. The HIV-1 transcriptional activator Tat has potent nucleic acid chaperoning activities in vitro. Nucleic Acids Res 2008, 36:3389-3400. 10.1093/nar/gkn177, 2425468, 18442994.
33. Yang M. Discoveries of Tat-TAR interaction inhibitors for HIV-1. Curr Drug Targets Infect Disord 2005, 5:433-444. 10.2174/156800505774912901, 16535863.
34. Davidson A, Leeper TC, Athanassiou Z, Patora-Komisarska K, Karn J, Robinson JA, Varani G. Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein. Proc Natl Acad Sci USA 2009, 106:11931-11936. 10.1073/pnas.0900629106, 2715490, 19584251.
35. Upert G, Di Giorgio A, Upadhyay A, Manvar D, Pandey N, Pandey VN, Patino N. Inhibition of HIV replication by cyclic and hairpin PNAs targeting the HIV-1 TAR RNA loop. J Nucleic Acids 2012, 2012:591025. doi:10.1155/2012/591025, 3457641, 23029603.
36. Hamasaki T, Okamoto M, Baba M. Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting cyclin T1/Tat interaction. Antimicrob Agents Chemother 2013, 57:1323-1331. 10.1128/AAC.01711-12, 3591921, 23274668.
37. Yedavalli VS, Jeang KT. Trimethylguanosine capping selectively promotes expression of Rev-dependent HIV-1 RNAs. Proc Natl Acad Sci USA 2010, 107:14787-14792. 10.1073/pnas.1009490107, 2930441, 20679221.
38. Dong H, Ren S, Li H, Shi PY. Separate molecules of West Nile virus methyltransferase can independently catalyze the N7 and 2′-O methylations of viral RNA cap. Virology 2008, 377:1-6. 10.1016/j.virol.2008.04.026, 2494700, 18501946.
39. HsuChen CC, Dubin DT. Di-and trimethylated congeners of 7-methylguanine in Sindbis virus mRNA. Nature 1976, 264:190-191. 10.1038/264190a0, 995206.
40. van Duijn LP, Kasperaitis M, Ameling C, Voorma HO. Additional methylation at the N(2)-position of the cap of 26S semliki forest virus late mRNA and initiation of translation. Virus Res 1986, 5:61-66. 10.1016/0168-1702(86)90065-1, 3751287.
41. Jia Y, Viswakarma N, Crawford SE, Sarkar J, Sambasiva Rao M, Karpus WJ, Kanwar YS, Zhu YJ, Reddy JK. Early embryonic lethality of mice with disrupted transcription cofactor PIMT/NCOA6IP/Tgs1 gene. Mech Dev 2012, 129:193-207. 10.1016/j.mod.2012.08.002, 3503541, 22982455.
42. Gordon RK, Ginalski K, Rudnicki WR, Rychlewski L, Pankaskie MC, Bujnicki JM, Chiang PK. Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem 2003, 270:3507-3517. 10.1046/j.1432-1033.2003.03726.x, 12919315.
43. Mayers DL, Mikovits JA, Joshi B, Hewlett IK, Estrada JS, Wolfe AD, Garcia GE, Doctor BP, Burke DS, Gordon RK, et al. Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3′-azido-3′-deoxythymidine-resistant HIV-1 strains. Proc Natl Acad Sci U S A 1995, 92:215-219. 10.1073/pnas.92.1.215, 42848, 7816820.
44. Hong JH, Kim SY, Oh CH, Yoo KH, Cho JH. Synthesis and antiviral evaluation of novel open-chain analogues of neplanocin A. Nucleosides Nucleotides Nucleic Acids 2006, 25:341-350. 10.1080/15257770500544578, 16629127.
45. Zhang H, Schinazi RF, Chu CK. Synthesis of neplanocin F analogues as potential antiviral agents. Bioorg Med Chem 2006, 14:8314-8322. 10.1016/j.bmc.2006.09.007, 16996741.
46. Vrolijk MM, Harwig A, Berkhout B, Das AT. Destabilization of the TAR hairpin leads to extension of the polyA hairpin and inhibition of HIV-1 polyadenylation. Retrovirology 2009, 6:13. 10.1186/1742-4690-6-13, 2645353, 19210761.
47. Soto-Rifo R, Rubilar PS, Limousin T, de Breyne S, Décimo D, Ohlmann T. DEAD-box protein DDX3 associates with eIF4F to promote translation of selected mRNAs. EMBO J 2012, 31:3745-3756. 10.1038/emboj.2012.220, 3442272, 22872150.
48. Soto-Rifo R, Rubilar PS, Ohlmann T. The DEAD-box helicase DDX3 substitutes for the cap-binding protein eIF4E to promote compartmentalized translation initiation of the HIV-1 genomic RNA. Nucleic Acids Res 2013, 41:6286-6299. 10.1093/nar/gkt306, 3695493, 23630313.
49. Mukherjee C, Patil DP, Kennedy BA, Bakthavachalu B, Bundschuh R, Schoenberg DR. Identification of cytoplasmic capping targets reveals a role for cap homeostasis in translation and mRNA stability. Cell Rep 2012, 2:674-684. 10.1016/j.celrep.2012.07.011, 3462258, 22921400.
50. Schrom EM, Moschall R, Schuch A, Bodem J. Regulation of retroviral polyadenylation. Adv Virus Res 2013, 85:1-24.
51. Shi Y, Di Giammartino DC, Taylor D, Sarkeshik A, Rice WJ, Yates JR, Frank J, Manley JL. Molecular architecture of the human pre-mRNA 3′ processing complex. Mol Cell 2009, 33:365-376. 10.1016/j.molcel.2008.12.028, 2946185, 19217410.
52. Palazzo AF, Akef A. Nuclear export as a key arbiter of " mRNA identity" in eukaryotes. Biochim Biophys Acta 1819, 2012:566-577.
53. Tian B, Manley JL. Alternative cleavage and polyadenylation: the long and short of it. Trends Biochem Sci 2013, 38:312-320. 10.1016/j.tibs.2013.03.005, 23632313.
54. Elkon R, Ugalde AP, Agami R. Alternative cleavage and polyadenylation: extent, regulation and function. Nat Rev Genet 2013, 14:496-506. 10.1038/nrg3482, 23774734.
55. Ji Z, Lee JY, Pan Z, Jiang B, Tian B. Progressive lengthening of 3′ untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development. Proc Natl Acad Sci U S A 2009, 106:7028-7033. 10.1073/pnas.0900028106, 2669788, 19372383.
56. Berkhout B. HIV-1 as RNA evolution machine. RNA Biol 2011, 8:225-229. 10.4161/rna.8.2.14801, 21358278.
57. An W, Telesnitsky A. Human immunodeficiency virus type 1 transductive recombination can occur frequently and in proportion to polyadenylation signal readthrough. J Virol 2004, 78:3419-3428. 10.1128/JVI.78.7.3419-3428.2004, 371070, 15016864.
58. Zaiss AK, Son S, Chang LJ. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 2002, 76:7209-7219. 10.1128/JVI.76.14.7209-7219.2002, 136337, 12072520.
59. Brown PH, Tiley LS, Cullen BR. Efficient polyadenylation within the human immunodeficiency virus type 1 long terminal repeat requires flanking U3-specific sequences. J Virol 1991, 65:3340-3343. 240993, 1851882.
60. Cherrington J, Ganem D. Regulation of polyadenylation in human immunodeficiency virus (HIV): contributions of promoter proximity and upstream sequences. EMBO J 1992, 11:1513-1524. 556600, 1373376.
61. Valsamakis A, Schek N, Alwine JC. Elements upstream of the AAUAAA within the human immunodeficiency virus polyadenylation signal are required for efficient polyadenylation in vitro. Mol Cell Biol 1992, 12:3699-3705. 360226, 1508176.
62. Graveley BR, Fleming ES, Gilmartin GM. RNA structure is a critical determinant of poly(A) site recognition by cleavage and polyadenylation specificity factor. Mol Cell Biol 1996, 16:4942-4951. 231496, 8756653.
63. Graveley BR, Gilmartin GM. A common mechanism for the enhancement of mRNA 3′ processing by U3 sequences in two distantly related lentiviruses. J Virol 1996, 70:1612-1617. 189984, 8627681.
64. Gilmartin GM, Fleming ES, Oetjen J, Graveley BR. CPSF recognition of an HIV-1 mRNA 3′-processing enhancer: multiple sequence contacts involved in poly(A) site definition. Genes Dev 1995, 9:72-83. 10.1101/gad.9.1.72, 7828853.
65. Gee AH, Kasprzak W, Shapiro BA. Structural differentiation of the HIV-1 polyA signals. J Biomol Struct Dyn 2006, 23:417-428. 10.1080/07391102.2006.10531236, 16363877.
66. Klasens BI, Thiesen M, Virtanen A, Berkhout B. The ability of the HIV-1 AAUAAA signal to bind polyadenylation factors is controlled by local RNA structure. Nucleic Acids Res 1999, 27:446-454. 10.1093/nar/27.2.446, 148199, 9862964.
67. Zhang W, Bryson DI, Crumpton JB, Wynn J, Santos WL. Targeting folded RNA: a branched peptide boronic acid that binds to a large surface area of HIV-1 RRE RNA. Org Biomol Chem 2013, 11:6263-6271. 10.1039/c3ob41053f, 23925474.
68. Ashe MP, Griffin P, James W, Proudfoot NJ. Poly(A) site selection in the HIV-1 provirus: inhibition of promoter-proximal polyadenylation by the downstream major splice donor site. Genes Dev 1995, 9:3008-3025. 10.1101/gad.9.23.3008, 7498796.
69. McLaren M, Asai K, Cochrane A. A novel function for Sam68: enhancement of HIV-1 RNA 3′ end processing. RNA 2004, 10:1119-1129. 10.1261/rna.5263904, 1370602, 15208447.
70. Knoepfel SA, Abad A, Abad X, Fortes P, Berkhout B. Design of modified U1i molecules against HIV-1 RNA. Antiviral Res 2012, 94:208-216. 10.1016/j.antiviral.2012.03.010, 22507247.
71. Sajic R, Lee K, Asai K, Sakac D, Branch DR, Upton C, Cochrane A. Use of modified U1 snRNAs to inhibit HIV-1 replication. Nucleic Acids Res 2007, 35:247-255. 10.1093/nar/gkl869, 1802557, 17158512.
72. Scott JM, Imperiale MJ. Promoter-proximal poly(A) sites are processed efficiently, but the RNA products are unstable in the nucleus. Mol Cell Biol 1997, 17:2127-2135. 232060, 9121461.
73. Andersen PK, Lykke-Andersen S, Jensen TH. Promoter-proximal polyadenylation sites reduce transcription activity. Genes Dev 2012, 26:2169-2179. 10.1101/gad.189126.112, 3465738, 23028143.
74. Valente ST, Gilmartin GM, Venkatarama K, Arriagada G, Goff SP. HIV-1 mRNA 3′ end processing is distinctively regulated by eIF3f, CDK11, and splice factor 9G8. Mol Cell 2009, 36:279-289. 10.1016/j.molcel.2009.10.004, 3068534, 19854136.
75. Hori T, Takeuchi H, Saito H, Sakuma R, Inagaki Y, Yamaoka S. A carboxy-terminally truncated human CPSF6 lacking residues encoded by exon 6 inhibits HIV-1 cDNA synthesis and promotes capsid disassembly. J Virol 2013, 87:7726-7736. 10.1128/JVI.00124-13, 23658440.
76. Fricke T, Valle-Casuso JC, White TE, Brandariz-Nuñez A, Bosche WJ, Reszka N, Gorelick R, Diaz-Griffero F. The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6. Retrovirology 2013, 10:46. 10.1186/1742-4690-10-46, 3695788, 23622145.
77. Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, KewalRamani VN, Chin JW, Towers GJ, James LC. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog 2012, 8:e1002896. 10.1371/journal.ppat.1002896, 10.1371/journal.ppat.1002896, 3431306, 22956906.
78. de la Vega L, Sánchez-Duffhues G, Fresno M, Schmitz ML, Muñoz E, Calzado MA. The 73 kDa subunit of the CPSF complex binds to the HIV-1 LTR promoter and functions as a negative regulatory factor that is inhibited by the HIV-1 Tat protein. J Mol Biol 2007, 372:317-330. 10.1016/j.jmb.2007.06.075, 17669424.
79. Calzado MA, Sancho R, Muñoz E. Human immunodeficiency virus type 1 Tat increases the expression of cleavage and polyadenylation specificity factor 73-kilodalton subunit modulating cellular and viral expression. J Virol 2004, 78:6846-6854. 10.1128/JVI.78.13.6846-6854.2004, 421638, 15194760.
80. Zhang Z, Klatt A, Henderson AJ, Gilmour DS. Transcription termination factor Pcf11 limits the processivity of Pol II on an HIV provirus to repress gene expression. Genes Dev 2007, 21:1609-1614. 10.1101/gad.1542707, 1899470, 17606639.
81. Mouland AJ, Coady M, Yao XJ, Cohen EA. Hypophosphorylation of poly(A) polymerase and increased polyadenylation activity are associated with human immunodeficiency virus type 1 Vpr expression. Virology 2002, 292:321-330. 10.1006/viro.2001.1261, 11878934.